Peptide
Tesamorelin
Tesamorelin (Egrifta)
The only FDA-approved growth-hormone-releasing hormone analog for reducing visceral fat. Approved for HIV lipodystrophy. Now being tested for age-related visceral adiposity and NAFLD.
Summary Can tesamorelin reduce harmful belly fat? Show / hide ↓
Tesamorelin is a prescription medicine approved in the United States for abnormal fat buildup linked to HIV treatment. It signals a small gland in the brain to release growth hormone, mainly targeting visceral fat, which is fat around the internal organs. Two large studies found about a 15% reduction in this fat after 26 weeks, while smaller studies in adults without HIV found reductions of about 10% to 15% over 12 to 26 weeks. A 2019 study also found less liver fat and improved markers linked to liver scarring in people with NAFLD, a type of fatty liver disease not caused by alcohol, but this use is not yet established. Injection-site reactions, fluid retention, and joint pain can occur, and there is no evidence that tesamorelin helps people live longer.
What this means for you: Tesamorelin has solid evidence for reducing visceral fat in people with HIV-related fat redistribution. Evidence for general weight-related belly fat and fatty liver is still early, and the treatment is expensive.
moderate evidenceTesamorelin is the outlier in the peptide category on this site: it is a real, licensed, well-studied drug, not a research chemical. Approved by the FDA in 2010 for HIV-associated lipodystrophy after two large phase 3 trials showed reductions in visceral adipose tissue of roughly 15 percent over 26 weeks.
Mechanistically, tesamorelin binds the pituitary GHRH receptor and produces a pulsatile release of growth hormone that mimics the endogenous physiologic pattern. This raises IGF-1 modestly and drives lipolysis in visceral fat depots preferentially over subcutaneous fat. Unlike direct GH administration, tesamorelin preserves the negative feedback loop through somatostatin, which limits supraphysiologic GH exposure.
The off-label longevity conversation centers on two extensions. First: age-related visceral adiposity, which drives insulin resistance, systemic inflammation, and cardiovascular risk. Several small trials in HIV-negative adults with abdominal obesity have shown roughly 10 to 15 percent reductions in visceral fat with 12 to 26 weeks of daily tesamorelin at 2 mg subcutaneous. Second: non-alcoholic fatty liver disease (NAFLD), where a 2019 trial in JAMA Internal Medicine reported significant reductions in hepatic fat and liver fibrosis markers.
Cost is the main gate. Egrifta lists at roughly 4000 to 5000 US dollars per month at pharmacy retail. Compounded tesamorelin from 503B pharmacies runs closer to 500 to 800 dollars per month for cash-pay patients. Research-chemical tesamorelin, sold outside the regulated system, is cheaper but subject to purity variability.
Side effect profile is manageable. Injection site reactions are common. Modest increases in IGF-1 are the pharmacodynamic target and are usually kept within reference range with proper dosing. Fluid retention and joint pain occur at higher rates than placebo. Long-term cancer risk from sustained elevated IGF-1 is theoretical but has not been documented in the HIV cohort followed for over a decade.
Our position: Tesamorelin sits at Tier 1 for visceral fat reduction in HIV lipodystrophy (approved indication, phase 3 evidence). Tier 3 for age-related visceral adiposity and NAFLD (smaller trials, promising, not yet definitive). Not tested for lifespan or all-cause mortality endpoints.
Further reading
Curated external sources for a deeper dive. External links open in a new tab.